Abstract

Reduction of the risk of asthma attacks is a major goal of current asthma management. We propose to derive a risk scale predicting asthma attacks based on the blood eosinophil count and exhaled nitric oxide. Biomarker-stratified trial-level attack rates were extracted and pooled from the control arms of the Novel START, CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, STRATOS 1-2 and DREAM trials (n=3051). These were used to derive rate ratios and the predicted asthma attack rate for different patient groups. The resultant prototype risk scale shows potential to predict asthma attacks, which may be prevented by anti-inflammatory treatment.

RAS ID

38858

Document Type

Journal Article

Date of Publication

2022

Funding Information

Oxford Respiratory NIHR BRC Welcome Trust

School

School of Medical and Health Sciences

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Publisher

BMJ Publishing Group

Comments

Couillard, S., Laugerud, A., Jabeen, M., Ramakrishnan, S., Melhorn, J., Hinks, T., & Pavord, I. (2022). Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax, 77(2), 199-202. https://doi.org/10.1136/thoraxjnl-2021-217325

Included in

Diseases Commons

Share

 
COinS
 

Link to publisher version (DOI)

10.1136/thoraxjnl-2021-217325